Searched for
DR LAL PATH LABS SHARE PRICE
Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Dr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomu...
- Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growthLaurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by r...
- Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% returnNuvama has reiterated its 'Buy' rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upsid...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Two Trades for Today: A diagnostics major for a 6% rise, a large-cap financial service stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equities extended losses for a fifth straight session, pressured by elevated oil prices and persistent FII outflows. Despite intrada...
- Unexpected gainer of trouble in the Gulf? 13 stocks from backend of the EV shift, with upside potential of up to 33%Most investors seeking exposure to the EV shift choose the obvious: A pure EV company; a scooter or car maker. They are the face of the tra...
- Rs 30,000 rent for a cramped Mumbai flat vs free 2 BHK: Doctor reveals why she left the city for a village lifeDr Garima Chauhan, an anesthesiologist, shared why she left Mumbai for a small town despite being a lifelong Mumbaikar. She compared her ex...
- Buy, Sell or Hold? Goldman Sachs maintains a buy on Eternal; Citi recommends sell rating on Dr Reddy’s Laboratories post Q1 resultsGoldman Sachs and Citi have issued fresh post-Q1 calls on three stocks. Goldman stays bullish on Eternal (Buy, target Rs 345, 21% upside) d...
- Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target pricesDr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Triveni Engineering shares adjust 38.5% as stock turns ex-demerger. What lies ahead for 95,000 shareholdersTriveni Engineering shares appeared to fall sharply after trading ex-demerger, but the decline reflected a technical price adjustment follo...
- ICMR licenses cancer, vaccine technologies to Emcure, Biological EThe Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment an...
- Risk is integral to the market; but there are different kinds of risk: 6 mid-cap stocks with upside potential of up to 21%We are in uncertain and volatile times. Does that mean investors should just sit out the downturn? While that is an option, the better opti...
- MSCI India rejig: Eternal likely to see highest inflows at $648 mn; Lenskart, Groww among Nuvama’s expected inclusionsMSCI’s August India Standard Index review could trigger major passive inflows, with Eternal expected to attract the highest at $648 million...
- China's Kimi K3 emerges as a low-cost rival to Anthropic's Fable 5China's Kimi K3 AI model is now challenging premium frontier models with its performance. It joins Meta's Muse Spark and Google's Antigravi...
- For investors with an over 2-year perspective: 5 mid- and small-cap stocks with an upside potential of up to 26%This is a market to be selective in, not brave in. The safer way to play a turn in the market is to stay with businesses whose demand does ...
- Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a qua...
Load More
